AQR Capital Management LLC Makes New Investment in Outlook Therapeutics, Inc. (NASDAQ:OTLK)

AQR Capital Management LLC bought a new stake in shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) in the 2nd quarter, HoldingsChannel.com reports. The fund bought 10,164 shares of the company’s stock, valued at approximately $75,000.

Other institutional investors have also recently made changes to their positions in the company. Squarepoint Ops LLC acquired a new stake in Outlook Therapeutics in the 2nd quarter worth about $232,000. Great Point Partners LLC lifted its position in shares of Outlook Therapeutics by 15.0% in the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock valued at $12,557,000 after acquiring an additional 221,510 shares in the last quarter. LVW Advisors LLC acquired a new stake in shares of Outlook Therapeutics in the second quarter valued at approximately $352,000. Finally, Rosalind Advisors Inc. increased its holdings in shares of Outlook Therapeutics by 44.3% in the second quarter. Rosalind Advisors Inc. now owns 450,000 shares of the company’s stock valued at $3,321,000 after purchasing an additional 138,225 shares during the last quarter. 11.20% of the stock is owned by hedge funds and other institutional investors.

Outlook Therapeutics Stock Up 3.3 %

Shares of NASDAQ OTLK opened at $5.31 on Friday. The business has a 50-day moving average of $6.40 and a two-hundred day moving average of $7.40. Outlook Therapeutics, Inc. has a 1 year low of $4.61 and a 1 year high of $18.00.

Outlook Therapeutics (NASDAQ:OTLK) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.23. Equities research analysts anticipate that Outlook Therapeutics, Inc. will post -3.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Chardan Capital reissued a “buy” rating and set a $53.00 target price on shares of Outlook Therapeutics in a research note on Friday, August 16th. Ascendiant Capital Markets cut their target price on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. BTIG Research restated a “buy” rating and set a $50.00 price target on shares of Outlook Therapeutics in a research report on Friday. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Outlook Therapeutics in a research report on Thursday, August 15th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $48.20.

Insiders Place Their Bets

In other news, CFO Lawrence A. Kenyon bought 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The stock was purchased at an average cost of $5.69 per share, with a total value of $28,450.00. Following the transaction, the chief financial officer now directly owns 5,946 shares in the company, valued at $33,832.74. This trade represents a 500.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 3.40% of the stock is owned by company insiders.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.